Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma

NCT00193973 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Trans Tasman Radiation Oncology Group

Collaborators